Partner Investment Management L.P. lifted its holdings in shares of Audentes Therapeutics Inc (NASDAQ:BOLD) by 227.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,852 shares of the biotechnology company’s stock after purchasing an additional 9,619 shares during the quarter. Partner Investment Management L.P.’s holdings in Audentes Therapeutics were worth $548,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BOLD. TD Asset Management Inc. grew its holdings in shares of Audentes Therapeutics by 19.3% during the 2nd quarter. TD Asset Management Inc. now owns 59,222 shares of the biotechnology company’s stock worth $2,263,000 after purchasing an additional 9,600 shares during the period. Los Angeles Capital Management & Equity Research Inc. purchased a new position in shares of Audentes Therapeutics during the 2nd quarter worth $232,000. Wells Fargo & Company MN grew its holdings in shares of Audentes Therapeutics by 29.5% during the 2nd quarter. Wells Fargo & Company MN now owns 398,155 shares of the biotechnology company’s stock worth $15,213,000 after purchasing an additional 90,618 shares during the period. Victory Capital Management Inc. lifted its stake in Audentes Therapeutics by 35.1% during the 2nd quarter. Victory Capital Management Inc. now owns 739,241 shares of the biotechnology company’s stock worth $28,246,000 after acquiring an additional 191,950 shares in the last quarter. Finally, Jennison Associates LLC lifted its stake in Audentes Therapeutics by 1.8% during the 2nd quarter. Jennison Associates LLC now owns 1,020,556 shares of the biotechnology company’s stock worth $38,995,000 after acquiring an additional 17,877 shares in the last quarter. Institutional investors and hedge funds own 84.48% of the company’s stock.

BOLD opened at $23.42 on Thursday. Audentes Therapeutics Inc has a 12-month low of $19.62 and a 12-month high of $46.18. The stock has a market cap of $998.52 million, a P/E ratio of -6.86 and a beta of 1.89.

Audentes Therapeutics (NASDAQ:BOLD) last posted its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.97) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.88) by ($0.09). During the same period in the previous year, the business earned ($0.88) earnings per share. Analysts forecast that Audentes Therapeutics Inc will post -3.42 earnings per share for the current year.

Several equities analysts recently issued reports on BOLD shares. ValuEngine lowered Audentes Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, October 12th. Wedbush decreased their target price on Audentes Therapeutics from $52.00 to $49.00 and set an “outperform” rating on the stock in a research note on Monday, October 8th. William Blair lowered Audentes Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 6th. HC Wainwright set a $40.00 target price on Audentes Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, September 25th. Finally, Guggenheim started coverage on Audentes Therapeutics in a research note on Tuesday, October 9th. They set a “neutral” rating on the stock. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $35.49.

In other Audentes Therapeutics news, VP Suyash Prasad sold 10,000 shares of the stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $36.88, for a total value of $368,800.00. Following the sale, the vice president now owns 100 shares of the company’s stock, valued at approximately $3,688. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Louis G. Lange sold 24,000 shares of the stock in a transaction dated Thursday, November 15th. The shares were sold at an average price of $22.49, for a total value of $539,760.00. Following the completion of the sale, the director now directly owns 345,799 shares in the company, valued at approximately $7,777,019.51. The disclosure for this sale can be found here. Insiders sold a total of 101,039 shares of company stock worth $3,465,020 in the last ninety days. 6.60% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This news story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.watchlistnews.com/audentes-therapeutics-inc-bold-shares-bought-by-partner-investment-management-l-p/2665544.html.

Audentes Therapeutics Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Read More: Institutional Investors

Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.